Close Menu

NEW YORK – Prometheus Biosciences said today that it has entered into a global strategic collaboration with Takeda Pharmaceutical to discover, develop, and commercialize therapies for inflammatory bowel disease.

The firms anticipate combining the Prometheus bioinformatics platform and advanced machine learning techniques with Takeda's expertise in drug development to deliver a new generation of IBD therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.